Home>Topics>>Lexicon Pharma (LXRX) +8.5% premarket after its LX1033 drug candidate for irritable bowel syndrome receives fast track status from the FDA.

Lexicon Pharma (LXRX) +8.5% premarket after its LX1033 drug candidate for irritable bowel syndrome receives fast track status from the FDA.

SeekingAlpha.com: SA Currents

Mon, 17 Dec 2012

Lexicon Pharma ( LXRX ) +8.5% premarket after its LX1033 drug candidate for irritable bowel syndrome receives fast track status from the FDA . Post your comment!
Content Partners